EE403 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in Germany

Abstract

Authors

F Kron L Reimeir R Welte Y. Rodriguez-Guadarrama F. van Hees N Smith R Blissett S Vadgama B Doble